Boehringer Ingelheim Selects Medidata Clinical Cloud

December 21, 2015

Boehringer Ingelheim will integrate Medidata’s study planning, data management, data analytics and RBM capabilities into multiple stages of its drug development process.

Medidata announced that Boehringer Ingelheim has selected the Medidata Clinical Cloud technology platform to support all of Boehringer Ingelheim's drug development programs. Boehringer Ingelheim will integrate Medidata’s study planning, data management, data analytics and risk-based monitoring (RBM) capabilities into multiple stages of its drug development process using Medidata Rave, Coder, Safety Gateway, Designer, Grants Manager and Insights, as well as its RBM solutions. The Medidata Clinical Cloud supports 10,000-plus clinical studies, 370,000 investigational sites and more than 2.7 million trial volunteers.

Read the full release.

Related Content:

News